ArticleFrontiers in toxicology2025
Unlocking liver physiology: comprehensive pathway maps for mechanistic understanding.
Article in Frontiers in toxicology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- From animal models to NAMs: a paradigm shift in developmental immunotoxicity testing.Archives of toxicology · 2026Review
- Cardiotoxicity adverse outcome pathway network: towards mechanistic and quantitative modelling.Frontiers in toxicology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aims: Methods: Two PMs were developed through manual literature curation, integrating data from established pathway resources and domain expert knowledge. Cell-type specificity was validated using Human Protein Atlas datasets. An interactive version is available online for exploration. Cross-comparison analysis with existing Adverse Outcome Pathway (AOP) networks was performed to benchmark physiological coverage and identify knowledge gaps. Results: The LiverLipidPM focuses on liver lipid metabolism, detailing pathways involved in fatty acid synthesis, triglycerides, cholesterol metabolism, and lipid catabolism in hepatocytes. And the LiverBilePM represents bile acid biosynthesis and secretion processes, detailing biosynthesis, transport, and secretion processes between hepatocytes and cholangiocytes. Both maps integrate metabolism with signaling pathways and regulatory networks. The interactive maps enable visualization of molecular pathways, linkage to external ontologies, and overlay of experimental data. Comparative analysis revealed unique mechanisms to each map and overlaps with existing AOP networks. Chemical-target queries identified new potential targets in both PMs, which might represent new molecular initiating events for AOP network extension. Conclusion: The developed liver PMs serve as valuable resources for hepatology research, with a special focus on hepatotoxicity, supporting the refinement of AOP networks and the development of human-oriented
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.